Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sariya Udayachalerm, Maranda G. Renouard, Thunyarat Anothaisintawee, Ammarin Thakkinstian, Sajesh K. Veettil & Nathorn Chaiyakunapruk. (2022) Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. Journal of Medical Economics 25:1, pages 26-37.
Read now
Read now
George N. Okoli, Yahya Al-Yousif, Viraj K. Reddy, Mê-Linh Lê, Christine J. Neilson & Ahmed M. Abou-Setta. (2022) The Number Needed to Vaccinate (NNV) against herpes zoster: a systematic review with meta-analysis. Infectious Diseases 54:5, pages 356-366.
Read now
Read now
Patricia R. Blank, Zanfina Ademi, Xiaoyan Lu, Thomas D. Szucs & Matthias Schwenkglenks. (2017) Herpes zoster vaccine: A health economic evaluation for Switzerland. Human Vaccines & Immunotherapeutics 13:7, pages 1495-1504.
Read now
Read now
Juan Luis Lopez-Belmonte, Ramón Cisterna, Angel Gil de Miguel, Caroline Guilmet, Florence Bianic & Mathieu Uhart. (2016) The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. Journal of Medical Economics 19:6, pages 576-586.
Read now
Read now
Emmanuelle Préaud, Mathieu Uhart, Katharina Böhm, Pamela Aidelsburger, Delphine Anger, Florence Bianic & Nathalie Largeron. (2015) Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Human Vaccines & Immunotherapeutics 11:4, pages 884-896.
Read now
Read now
Pieter T de Boer, Jan C Wilschut & Maarten J Postma. (2014) Cost-effectiveness of vaccination against herpes zoster. Human Vaccines & Immunotherapeutics 10:7, pages 2048-2061.
Read now
Read now
Xavier Bresse, Lieven Annemans, Emmanuelle Préaud, Karine Bloch, Gérard Duru & Aline Gauthier. (2013) Vaccination against herpes zoster and postherpetic neuralgia in France: a cost–effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 13:3, pages 393-406.
Read now
Read now
Mélanie Drolet, Michael N. Oxman, Myron J. Levin, Kenneth E. Schmader, Robert W. Johnson, David Patrick, James A. Mansi & Marc Brisson. (2013) Vaccination against herpes zoster in developed countries. Human Vaccines & Immunotherapeutics 9:5, pages 1177-1184.
Read now
Read now
Monica Tontodonati, Tamara Ursini, Ennio Polilli, Francesco Vadini, Francesco Di Masi, Damiano Volpone & Giustino Parruti. (2012) Post-herpetic neuralgia. International Journal of General Medicine 5, pages 861-871.
Read now
Read now
Articles from other publishers (28)
Christopher J. Cadham, Marie Knoll, Luz María Sánchez-Romero, K. Michael Cummings, Clifford E. Douglas, Alex Liber, David Mendez, Rafael Meza, Ritesh Mistry, Aylin Sertkaya, Nargiz Travis & David T. Levy. (2021) The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review. Medical Decision Making 42:5, pages 684-703.
Crossref
Crossref
Pierre-Olivier Lang & Richard Aspinall. (2019) Vaccination for quality of life: herpes–zoster vaccines. Aging Clinical and Experimental Research 33:4, pages 1113-1122.
Crossref
Crossref
Michael Harvey, Lisa A. Prosser, Angela M. Rose, Ismael R. Ortega-Sanchez & Rafael Harpaz. (2020) Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. Pain 161:2, pages 361-368.
Crossref
Crossref
Lisa A. ProsserRafael HarpazAngela M. RoseAcham GebremariamAngela GuoIsmael R. Ortega-SanchezFangjun ZhouKathleen Dooling. (2019) A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Annals of Internal Medicine 170:6, pages 380.
Crossref
Crossref
Edward T. Chiyaka, Van T. Nghiem, Lu Zhang, Abhishek Deshpande, Patricia Dolan Mullen & Phuc Le. (2018) Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. PharmacoEconomics 37:2, pages 169-200.
Crossref
Crossref
M.J. Harvey, B.T. Denton, L.A. Prosser & D.W. Hutton. (2018) Determining the optimal strategy for the live-attenuated herpes zoster vaccine in adults. Vaccine 36:41, pages 6237-6247.
Crossref
Crossref
Joke Bilcke, Frederik Verelst & Philippe Beutels. (2018) Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination. Medical Decision Making 38:6, pages 730-745.
Crossref
Crossref
F. Précausta, S. Majzoub, G. Vandermeer, R. Buzele, C. Queiros, B. Laure & P.-J. Pisella. (2017) Syndrome de l’apex secondaire à un zona ophtalmique. Journal Français d'Ophtalmologie 40:10, pages e385-e388.
Crossref
Crossref
Shu-ling Hoshi, Masahide Kondo & Ichiro Okubo. (2017) Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine 35:24, pages 3264-3271.
Crossref
Crossref
Melanie Drolet. 2017. Herpes Zoster: Postherpetic Neuralgia and Other Complications. Herpes Zoster: Postherpetic Neuralgia and Other Complications
119
140
.
Bernhard Ultsch, Oliver Damm, Philippe Beutels, Joke Bilcke, Bernd Brüggenjürgen, Andreas Gerber-Grote, Wolfgang Greiner, Germaine Hanquet, Raymond Hutubessy, Mark Jit, Mirjam Knol, Rüdiger von Kries, Alexander Kuhlmann, Daniel Levy-Bruhl, Matthias Perleth, Maarten Postma, Heini Salo, Uwe Siebert, Jürgen Wasem & Ole Wichmann. (2015) Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PharmacoEconomics 34:3, pages 227-244.
Crossref
Crossref
Nabila Ferahta, Imene Achek, Julie Dubourg & Pierre-Olivier Lang. (2016) Les vaccins contre le zona : efficacité, sécurité, et rapport coût/bénéfices. La Presse Médicale 45:2, pages 162-176.
Crossref
Crossref
Silvia Coretti, Paola Codella, Federica Romano, Matteo Ruggeri & Americo Cicchetti. (2016) COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. International Journal of Technology Assessment in Health Care 32:4, pages 233-240.
Crossref
Crossref
Oliver Damm, Bernhard Ultsch, Johannes Horn, Rafael T. Mikolajczyk, Wolfgang Greiner & Ole Wichmann. (2015) Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 15:1.
Crossref
Crossref
Adam Gater, Mathieu Uhart, Rachael McCool & Emmanuelle Préaud. (2015) The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. BMC Public Health 15:1.
Crossref
Crossref
Stephen J. Cook & Dennis K. Flaherty. (2015) Review of the Persistence of Herpes Zoster Vaccine Efficacy in Clinical Trials. Clinical Therapeutics 37:11, pages 2388-2397.
Crossref
Crossref
Robert W. Johnson, Marie-José Alvarez-Pasquin, Marc Bijl, Elisabetta Franco, Jacques Gaillat, João G. Clara, Marc Labetoulle, Jean-Pierre Michel, Luigi Naldi, Luis S. Sanmarti & Thomas Weinke. (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Advances in Vaccines 3:4, pages 109-120.
Crossref
Crossref
R. J. Whitley. (2014) Editorial Commentary: Waning Efficacy of the Herpes Zoster Vaccine. Clinical Infectious Diseases 60:6, pages 910-911.
Crossref
Crossref
Ahmed Hashim, Vica Dang, Shelly Bolotin & Natasha S. Crowcroft. (2015) How and why researchers use the number needed to vaccinate to inform decision making—A systematic review. Vaccine 33:6, pages 753-758.
Crossref
Crossref
Alexander D. Peden, Stephenson B. Strobel & Evelyn L. Forget. (2014) Is herpes zoster vaccination likely to be cost-effective in Canada?. Canadian Journal of Public Health 105:4, pages e287-e295.
Crossref
Crossref
Kosuke Kawai, Emmanuelle Preaud, Florence Baron-Papillon, Nathalie Largeron & Camilo J. Acosta. (2014) Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine 32:15, pages 1645-1653.
Crossref
Crossref
Bernhard Ultsch, Felix Weidemann, Thomas Reinhold, Anette Siedler, Gérard Krause & Ole Wichmann. (2013) Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Services Research 13:1.
Crossref
Crossref
Bernhard Ultsch, Ingrid Köster, Thomas Reinhold, Anette Siedler, Gérard Krause, Andrea Icks, Ingrid Schubert & Ole Wichmann. (2012) Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. The European Journal of Health Economics 14:6, pages 1015-1026.
Crossref
Crossref
Gillian M. Keating. (2013) Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years. Drugs 73:11, pages 1227-1244.
Crossref
Crossref
Thomas D. Szucs & Alena M. Pfeil. (2013) A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination. PharmacoEconomics 31:2, pages 125-136.
Crossref
Crossref
J. BILCKE, B. OGUNJIMI, C. MARAIS, F. DE SMET, M. CALLENS, K. CALLAERT, E. VAN KERSCHAVER, J. RAMET, P. VAN DAMME & P. BEUTELS. (2012) The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiology and Infection 140:11, pages 2096-2109.
Crossref
Crossref
Joke Bilcke, Benson Ogunjimi, Frank Hulstaert, Pierre Van Damme, Niel Hens & Philippe Beutels. (2012) Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. Vaccine 30:17, pages 2795-2800.
Crossref
Crossref
Joke Bilcke, Christiaan Marais, Benson Ogunjimi, Lander Willem, Niel Hens & Philippe Beutels. (2012) Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 30:3, pages 675-684.
Crossref
Crossref